Press Release, Lund September 25, 2020 Hamlet Pharma is pleased to announce that the clinical development of Alpha1H therapy in bladder cancer will be accelerated….
Read More
Press Release, Lund September 4, 2020 The board of Hamlet Pharma has decided to accept a proposal from Linnane Pharma to terminate the patent license…
Press Release, Lund June 12, 2020 Hamlet Pharma is proud to announce that the contract with the European union has been signed, granting pre-payment of…
Press Release, Lund May 12, 2020 A patent licensing agreement has been signed between Hamlet Pharma AB and Linnane Pharma AB to secure the development…
Newsletter 2020 – Issue 2; Business Update – Hamlet Pharma receives EU grant for €2.2M Last month, members of the Hamlet Pharma Executive Team travelled…
Newsletter 2020 – Issue 1; Bladder Cancer “Bladder cancer (BC) has the highest lifetime treatment costs per patient (pp) of all cancers, followed by colorectal-,…
Press Release, Lund February 5, 2020 Alpha1H shows significant promise as a new and effective cancer drug with low toxicity in a clinical bladder cancer…
Pressmeddelande, Lund 3 februari, 2020 Hamlet Pharma tillförs 12,95 miljoner SEK genom inlösen av teckningsoptioner utfärdade i samband med den riktade emissionen från den 1…
Press Release, Lund December 18, 2019 Hamlet Pharma is on track with its plans to engage in a clinical trial of Alpha1H for the treatment…
BioWorld. November 6, 2019 By Cormac Sheridan – DUBLIN – Hamlet Pharma AB is about to embark on the next phase in the clinical development…
Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…